TIMP3 is a multifunctional extracellular matrix-bound protease inhibitor that regulates tissue homeostasis through reversible inhibition of matrix metalloproteinases (MMPs-1, -2, -3, -7, -9, -13, -14, -15) and ADAM proteases (ADAM10, ADAM17) 1. Beyond ECM remodeling, TIMP3 functions as a potent tumor suppressor through anti-angiogenic mechanisms, directly interacting with VEGF receptor-2 to prevent ligand binding and inducing caspase-independent apoptosis in endothelial cells via focal adhesion kinase inhibition [UniProt data]. TIMP3 exhibits broad clinical relevance across multiple diseases: lung cancer progression correlates with reduced TIMP3 expression downstream of the USP10-KLF4 regulatory axis 1; diabetic nephropathy is characterized by TIMP3 loss with therapeutic potential through restoration 2; genetic polymorphisms associate with primary open-angle glaucoma and ankylosing spondylitis susceptibility 34. Additionally, TIMP3 modulates somatosensory pain signaling in satellite glial cells, with paclitaxel-induced neuropathic pain reversible through TIMP3 protein delivery 5. In hepatocellular carcinoma, TIMP3 acts as a tumor suppressor regulated by the circDCUN1D4/miR-590-5p axis 6, and in breast cancer, TIMP3 downregulation accompanies increased cellular invasion 7. Macrophage-specific TIMP3 regulation through Nrf2 binding modulates inflammatory responses in liver ischemia-reperfusion injury 8.